Corporate Citizenship covers the various theoretical and philosophical frameworks relating to corporate citizenship.

The title provides students with a broad range of examples, cases and situations that encourage students to apply the knowledge in a critical manner.

Lanna Buddhism is a variant of Theravada Buddhism that evolved between the 13th and 16th centuries in northern Thailand and spread to neighbouring areas of the Upper Mekong region. A salient feature is the belief in charismatic monks, some of whom are renowned for their asceticism, supernatural powers and strivings to recreate a utopian 'Buddha-land'. Issues highlighted in the book are the relationship of these charismatic monks to the state and state-controlled monkhood (sangha), the tendency for religious construction to spill over into economic development activities, and the diversity of lowland and highland devotional communities from Thailand and Myanmar.The book also explores contemporary influences on this religious tradition: the continuing marginalization of highland minorities and consequent devotion to messianic leaders, the incorporation for Lanna holy men into a national constellation of popular charismatic monks, the commercialization of Buddhism, and the patronage of wealthy urban elites.Charismatic Monks of Lanna Buddhism will appeal to scholars within the fields of Buddhist studies, Thai studies and the anthropology of religion as well as to those with an interest in the study of contemporary religious change in Thailand.

There is little doubt that children with gender problems suffer psychologically. But when clinicians are confronted with such cases, they often make controversial choices without the benefit of a substantial knowledge base.

Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices presents an overview of the research, clinical insights, and ethical dilemmas relevant to clinicians who treat intersex youth and their families. Exploring gender development from a cross-cultural perspective, esteemed scholar Peggy T. Cohen-Kettenis and experienced practitioner Friedemann Pfäfflin focus on assessment, diagnosis, and treatment issues. To bridge research and practical application, they include numerous case studies, definitions of relevant terminology, and salient chapter summaries.

Clinically oriented, this comprehensive volume examines

• Gender development, identity, and segregation in sexual and psychosexual differentiation
• Subtypes and multiple theories of atypical gender development
• Evaluation, diagnosis, and intervention techniques for gender identity disorders
• Eligibility issues for reversible, partially reversible, and irreversible sex reassignment intervention
• Legal and ethical guidelines for the clinical management of gender problems in children and adolescents

Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices offers an authoritative examination of sexual, psychosexual, and gender differentiation in children and adolescents. Combining empirical knowledge and in-depth research, the authors supply practitioners with the tools to effectively treat intersex, gender dysphoric, and gender variant youth.

An indispensable resource for mental health, medical, and educational professionals who work with children and adolescents, Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices is also an excellent supplementary text for advanced undergraduate, graduate, and credential students in developmental and clinical psychology, pediatric psychiatry, pediatric nursing, and gender studies courses.

The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify. The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States. With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify. The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States. With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

For the past forty years, Cheryl Cohen Greene has worked as a surrogate partner, helping clients to confront, consider, and ultimately accept their sexuality. In this riveting memoir, Cohen Greene shares some of her most moving cases, and also reveals her own sexual coming-of-age. Beginning with a rigid Catholic upbringing in the 1950s, where she was taught to think sex and sexual desires were unnatural and wrong, Cohen Greene struggled to reconcile her sexual identity. An Intimate Life offers a candid look into the personal and professional life of a surrogate partner, examining the cultural and emotional ramifications of pursuing something most people do not immediately understand. The memoir opens with Cohen Greene's work with Berkeley-based poet and journalist Mark O'Brien, whose essay "On Seeing A Sex Surrogate" was adapted into a major motion picture titled "The Sessions," which was released nationwide in October 2012.

There is little doubt that children with gender problems suffer psychologically. But when clinicians are confronted with such cases, they often make controversial choices without the benefit of a substantial knowledge base.

Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices presents an overview of the research, clinical insights, and ethical dilemmas relevant to clinicians who treat intersex youth and their families. Exploring gender development from a cross-cultural perspective, esteemed scholar Peggy T. Cohen-Kettenis and experienced practitioner Friedemann Pfäfflin focus on assessment, diagnosis, and treatment issues. To bridge research and practical application, they include numerous case studies, definitions of relevant terminology, and salient chapter summaries.

Clinically oriented, this comprehensive volume examines

• Gender development, identity, and segregation in sexual and psychosexual differentiation
• Subtypes and multiple theories of atypical gender development
• Evaluation, diagnosis, and intervention techniques for gender identity disorders
• Eligibility issues for reversible, partially reversible, and irreversible sex reassignment intervention
• Legal and ethical guidelines for the clinical management of gender problems in children and adolescents

Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices offers an authoritative examination of sexual, psychosexual, and gender differentiation in children and adolescents. Combining empirical knowledge and in-depth research, the authors supply practitioners with the tools to effectively treat intersex, gender dysphoric, and gender variant youth.

An indispensable resource for mental health, medical, and educational professionals who work with children and adolescents, Transgenderism and Intersexuality in Childhood and Adolescence: Making Choices is also an excellent supplementary text for advanced undergraduate, graduate, and credential students in developmental and clinical psychology, pediatric psychiatry, pediatric nursing, and gender studies courses.